About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:6458735
Allelic
Composition
Tg(Thy1/THY1)T6Gsv/0
Genetic
Background
involves: C57BL/10 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• mice injected with an anti-Thy1a (Thy1.1) mAb develop albuminuria; persistence of albuminuria is dose dependent
• parietal epithelial cells show vacuolization and detachment at day 1 of anti-Thy1.1 mAb injection
• parietal epithelial cells are activated with enlarged nuclei and prominent nucleoli at days 6 and 7 post anti-Thy1.1 mAb injection
• glomeruli show an increase of epithelial cells in Bowman's space at days 6 and 7 post anti-Thy1.1 mAb injection
• enlarged Bowman's space due to collapse of the glomerular tuft at day 1 of anti-Thy1.1 mAb injection, indicating ischemia
• the number of foot processes per 10 um glomerular basement membrane decreases over time in anti-Thy1a (Thy1.1) mAb injected mice
• however, no podocyte detachment of denudation of the glomerular basement membrane or changes in glomerular basement membrane thickness are seen at 10 min or 8 hours after anti-Thy1a (Thy1.1) mAb injection
• global podocyte alterations with foot process effacement and mirocivllius transformation is seen at days 1 and 3 post anti-Thy1.1 mAb injection
• however, podocyte detachment or areas of denuded glomerular basement membrane are not seen
• the diameter of remaining slit pores is decreased in anti-Thy1a (Thy1.1) mAb injected mice
• affected glomerular segments show hypertrophic podocytes, with extensive vacuolization, resorption droplets, and formation of pseudocysts at days 6 and 7 post anti-Thy1.1 mAb injection
• affected glomerular segments show hypertrophic podocytes, with extensive vacuolization at days 6 and 7 post anti-Thy1.1 mAb injection
• collapse of the glomerular tuft at day 1 of anti-Thy1.1 mAb injection
• glomeruli show segmental collapse of the capillary tuft space at days 6 and 7 post anti-Thy1.1 mAb injection
• mild mesangial hypercelluarity is sporadically seen at days 6 and 7 post anti-Thy1.1 mAb injection
• mice injected with an anti-Thy1a (Thy1.1) mAb develop focal segmental glomerulosclerosis (FSGS) lesions within 3 weeks (J:294621)
• focal segmental glomerulosclerosis lesions are first seen at days 6 and 7 post anti-Thy1.1 mAb injection, with tuft adhesions to Bowman's capsule (J:294621)
• FSGS lesions resemble the collapsing variant of human FSGS (J:294621)
• FSGS lesions, with tuft adhesions to Bowman's capsule, are seen in 11% and 26% of glomeruli at days 6 and 7 post anti-Thy1.1 mAb injection, respectively (J:294621)
• at day 21 post anti-Thy1.1 mAb injection, the percentage of glomeruli with lesions does not increase but the lesions are more advanced, showing a high degree of extracellular matrix accumulation which leads to the formation of segmental or global scars (J:294621)
• tubular lumens exhibit many hyaline protein casts at day 1 of anti-Thy1.1 mAb injection (J:294621)
• mice injected with an anti-Thy1a (Thy1.1) mAb develop focal glomerulosclerosis (J:294728)
• adhesions (continuity of extracellular matrix (ECM) between the capillary tuft and Bowmans capsule) form by thin strands of ECM that are located in between the epithelial cells in Bowman's space at days 6 and 7 post anti-Thy1.1 mAb injection
• mice injected with an anti-Thy1a (Thy1.1) mAb exhibit protein casts in distal tubules and collecting ducts already at 10 min after anti-Thy1a (Thy1.1) mAb administration
• 8 hours after anti-Thy1a (Thy1.1) mAb injection, protein casts are seen in all types of tubules and in glomeruli and proximal tubules exhibit a large number of resorption vacuoles and damaged cells
• proximal tubular epithelial cells exhibit damage at day 1 of anti-Thy1.1 mAb injection
• mice injected with an anti-Thy1a (Thy1.1) mAb exhibit dilated tubules
• enlarged Bowman's space due to collapse of the glomerular tuft at day 1 of anti-Thy1.1 mAb injection, indicating ischemia (J:294621)
• glomeruli are no longer ischemic at day 3 post anti-Thy1.1 mAb injection (J:294621)
• glomeruli become increasingly ischemic after anti-Thy1a (Thy1.1) mAb injection, leading to an enlarged Bowman's space due to the collapse of the glomerular tuft (J:294728)
• mice injected with a high dose (2000 ug) of anti-Thy1a (Thy1.1) mAb exhibit very low urine volumes

hematopoietic system
• endocapillary neutrophils are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection
• mononuclear cells are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection
• endocapillary foam cells are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection

homeostasis/metabolism
• mice injected with an anti-Thy1a (Thy1.1) mAb develop albuminuria; persistence of albuminuria is dose dependent

immune system
• endocapillary neutrophils are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection
• mononuclear cells are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection
• endocapillary foam cells are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection

cellular
• endocapillary foam cells are sporadically seen in the kidney at days 6 and 7 post anti-Thy1.1 mAb injection

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
focal segmental glomerulosclerosis DOID:1312 OMIM:PS603278
J:294621 , J:294728


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/23/2024
MGI 6.23
The Jackson Laboratory